This series on “Neoadjuvant/Adjuvant Treatment for Early Breast Cancer” is edited by Yutaka Yamamoto, Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; and Takayuki Ueno, Breast Surgical Oncology, The Cancer Institute Hospital of JFCR Tokyo, Japan.
The prognosis of primary breast cancer has improved over time. The reason for the improvement of patients’ prognosis has been greatly contributed by advances in standard treatment as well as the widespread use of mammography screening for breast cancer. The goal of adjuvant systemic treatment for primary breast cancer is to control micrometastases that cannot be detected before the start of initial treatment such as surgery and neoadjuvant systemic treatment for primary tumor, thereby reducing recurrence and consequently prolonging survival. Adjuvant systemic treatment also plays a major role in suppressing local recurrence as well as distant metastases.
The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer
The series “Neoadjuvant/adjuvant Treatment for Early Breast Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Yutaka Yamamoto and Takayuki Ueno served as the unpaid Guest Editors for the series.